Clinical outcomes are generally worse for black vs nonblack renal allograft recipients.
| INTRODUC TI ON
Black renal allograft recipients administered calcineurin inhibitorbased or mammalian target of rapamycin (mTOR) inhibitor-based immunosuppression have poorer outcomes than nonblacks. Registry data show acute rejection (AR) rates at 1 year post-transplant to be significantly higher in black vs nonblack patients. 1, 2 Graft loss rates at 5 years post-transplant are also higher 3,4 -independent of living or deceased donor kidney status. 3 Racial disparities in kidney transplant outcomes have been attributed to immunologic, pharmacokinetic, and socioeconomic factors. 5 In vitro testing performed prior to transplantation has shown black patients to display more intense, nonspecific immunoreactivity than whites. 6 Black individuals also exhibit increased expression of co-stimulatory molecules and/or cytokines. 7, 8 These immunologic
properties may negatively impact graft survival. [6] [7] [8] The pharmacokinetics of several immunosuppressive drugs vary by race. The bioavailability of calcineurin and mTOR inhibitors is lower in blacks vs whites, 1,9-11 and mycophenolate mofetil is cleared more rapidly in black vs white renal allograft recipients. 12, 13 Thus, the higher rates of graft failure among black kidney transplant recipients may result from inadequate immunosuppression. The role of socioeconomic factors is controversial, 5, 14 as it may be confounded by racial differences in income, healthcare access, and insurance coverage. For example, black and white Canadian renal allograft recipients have similar graft survival rates. 15 Such data, which contrast with those from US renal transplant populations, 3, 4, 16 may be due to Canadians having access to free health care, including the cost of transplantation and post-transplantation follow-up. 15 However, in a US retrospective analysis, a graft survival disadvantage persisted among black renal allograft recipients, independent of whether they had received universal health care from the Department of Veterans
Affairs. 17 The available data on racial disparities in kidney transplant recipients derive from patients treated with calcineurin or mTOR inhibitors. The calcineurin inhibitors are potentially nephrotoxic, which may contribute to graft dysfunction and loss. [18] [19] [20] [21] [22] The mTOR inhibitors are not directly nephrotoxic, but sirolimus and everolimus are poorly tolerated, and both may be associated with worsening allograft function (increased proteinuria) in kidney transplant recipients with pre-existing renal parenchymal damage. [23] [24] [25] Moreover, everolimus carries a black box warning related to an increased risk of renal allograft thrombosis. 26 While there is a need to optimize immunosuppressive regimens in all kidney transplant recipients, this is particularly acute for black patients, given their predisposition to poorer post-transplant outcomes.
Belatacept is a selective T-cell co-stimulation blocker indicated for preventing organ rejection in adult kidney transplant recipients. BENEFIT-Extended Criteria Donors (BENEFIT-EXT) had similar designs, except that patients in BENEFIT were transplanted with a living or standard criteria deceased donor kidney, 28 while patients in BENEFIT-EXT received an extended criteria donor kidney. 29 In intention to treat analyses performed at 7 years post-transplant, belatacept was associated with superior graft survival vs cyclosporine in BENEFIT 30 and similar graft survival vs cyclosporine in BENEFIT-EXT. 31 In both studies, renal function was superior in belatacepttreated vs cyclosporine-treated patients. 30, 31 In the present post hoc analysis, outcomes at 7 years post-transplant were compared in black vs nonblack patients participating in BENEFIT and BENEFIT-EXT.
| ME THODS

| Study designs
The designs of BENEFIT (ClinicalTrials.gov identifier: NCT00256750) and BENEFIT-EXT (ClinicalTrials.gov identifier: NCT00114777) have been published. 28, 29 Briefly, BENEFIT and BENEFIT-EXT were 3-year, international, multicenter, randomized, partially blinded, activecontrolled, parallel-group, phase 3 studies of de novo adult kidney transplant recipients. Patients in BENEFIT received a living or standard criteria deceased donor kidney, 28 while patients in BENEFIT-EXT received an extended criteria donor kidney. 29 Extended criteria donor kidneys were protocol defined as those from donors aged ≥60 years; those from donors aged 50-59 years with ≥2 other risk factors (death due to cerebrovascular accident, history of hypertension, or terminal serum creatinine level >1.5 mg/dL); those with an respectively, were black. Time to death or graft loss was similar in blacks and nonblacks. For both subgroups, estimated mean GFR increased over 7 years for belatacept, but declined for cyclosporine. Outcomes were similar in belatacept-treated black and nonblack patients. Due to the small number of black patients, these results must be interpreted with caution.
K E Y W O R D S
acute rejection, cadaver organ transplantation, clinical trial, kidney, kidney transplantation, renal function anticipated cold ischemia time ≥24 hours; and those from nonheartbeating donors (donation after cardiac death). 29 Patients were randomized (1:1:1) to receive maintenance immunosuppression with a belatacept MI-based, belatacept LI-based, or cyclosporine-based regimen. All patients received basiliximab induction, mycophenolate mofetil, and corticosteroids. 28, 29 If approved by the treating physician, patients were allowed to continue study treatment beyond 3 years with additional written informed consent and continuation of the immunosuppressive regimen to which they had been randomized. 32, 33 For the present analysis, patients in each study were categorized as black or nonblack; race was self-identified.
Both studies were conducted in accordance with the principles outlined in the Declaration of Helsinki. The institutional review boards/ethics committees at participating sites approved the study protocols, and all patients provided written informed consent.
| Outcomes and statistics
Efficacy and safety from randomization to month 84 (year 7) were examined post hoc in black and nonblack patients and analyzed separately for BENEFIT and BENEFIT-EXT. Analyses were performed on all evaluable patients, assessed per the intention to treat principle at 84 months post-transplant. The evaluable population was composed of patients who were alive and observable at 84 months postrandomization or who had died or experienced graft loss by month 84.
For the examination of time to death or graft loss, patients were stratified into 1 of 6 subgroups based on race and treatment assignment. Data are summarized using Kaplan-Meier curves and event rates. Hazard ratios and 95% confidence intervals (CIs) at month 84 were calculated from 2 models of Cox regression. In the first model, race and treatment were regarded as independent variables. In the second model, the interaction between treatment and race was considered; cyclosporine-treated nonblack patients served as the reference population, with no adjustment for multiplicity.
The Kaplan-Meier method was used to assess a combined end point comprising time to first occurrence of death, graft loss, or estimated glomerular filtration rate (GFR) <30 mL/ values that were missing due to death or graft loss were imputed as zero; the same models were used as for the analyses without imputation.
Adverse events were mapped to terms from the Medical Dictionary for Regulatory Activities version 17.0 and expressed
F I G U R E 1 Patient numbers by race and treatment allocation in (A) BENEFIT and (B) BENEFIT-EXT. MI, more intense; LI, less intense
Randomized and transplanted N=666
Randomized and transplanted N=543
as incidence rates adjusted per 100 person-years of treatment exposure.
| RE SULTS
| BENEFIT: Patients
In total, 8.3% (55/666) of patients in BENEFIT were black ( Figure 1A ).
Compared with nonblacks, a greater percentage of blacks were from North America and had diabetes or hypertensive nephrosclerosis as the reported cause of end-stage renal disease (Table 1) . Table S1 summarizes the duration of follow-up by race in each treatment arm. 
| BENEFIT: Efficacy
| BENEFIT: Renal function
In both racial subgroups, estimated mean GFR increased over 7 years for belatacept-based immunosuppression, but declined for year. Relative to cyclosporine, the slope estimates in the nonblack subgroup differed for belatacept MI (P < .0001) and LI (P < .0001).
Sensitivity analyses in which GFR values that were missing due to patient death or graft loss were imputed as zero yielded similar results ( Figure S2 ).
| BENEFIT: Safety
Other than any-grade fungal infections, which were reported more frequently among black vs nonblack cyclosporine-treated patients (16.34 vs 7.00 cases per 100 person-years of exposure, respectively), no notable differences in safety were seen between racial subgroups in any treatment arm (Table S4) . No black patient developed post-transplant lymphoproliferative disorder (PTLD) by month 84. Seven nonblack patients had PTLD by month 84 (belatacept MI, n = 3; belatacept LI, n = 2; cyclosporine, n = 2).
| BENEFIT-EXT: Patients
In total, 13.1% (71/543) of patients in BENEFIT-EXT were black ( Figure 1B) . Compared with nonblacks, a greater percentage of blacks were from North America and had hypertensive nephrosclerosis as the reported cause of end-stage renal disease (Table 1 ).
| BENEFIT-EXT: Efficacy
In the black subgroup, 56.0% ( 
| BENEFIT-EXT: Renal function
In both racial subgroups, estimated mean GFR increased over 7 years for belatacept-based immunosuppression, but declined for cyclosporine-based treatment ( Figure 5 ). For all treatment arms, estimated mean GFR was similar for blacks and nonblacks over time. The estimated differences in GFR significantly favored belatacept-based vs cyclosporine-based immunosuppression in the black (P = .0005
for overall treatment effect) and nonblack cohorts (P < .0001 for overall treatment effect). per year, respectively. Relative to cyclosporine, the slope estimates in nonblack patients differed for belatacept MI (P = .0012) and LI (P = .0001). Sensitivity analyses in which GFR values that were missing due to patient death or graft loss were imputed as zero yielded similar trends, but statistical significance was lost ( Figure S4 ).
| BENEFIT-EXT: Safety
Other than serious infections, which were reported more frequently among black vs nonblack cyclosporine-treated patients (30.86 vs 19.23 cases per 100 person-years of exposure, respectively), no notable differences in safety were seen between racial subgroups in any treatment arm (Table S4) . By month 84, PTLD was reported in 1 Epstein-Barr virus negative black patient randomized to belatacept LI and 8 nonblack patients (belatacept MI, n = 2; belatacept LI, n = 5; cyclosporine, n = 1).
| D ISCUSS I ON
While calcineurin inhibitor-treated black kidney transplant recipients typically have poorer outcomes than calcineurin inhibitortreated nonblacks, 1, 2, 35 the results from these post hoc analyses of BENEFIT and BENEFIT-EXT show that efficacy and safety are similar in belatacept-treated black and nonblack patients. In BENEFIT,
Kaplan-Meier estimated rates of death or graft loss at month 84 ranged from 0% to 13.0% in belatacept-treated black patients and 12.8%-13.6% in belatacept-treated nonblack patients. Notably, these rates are consistent with those reported in the overall intention to treat populations (12.7%-12.8%). 30 In contrast to published data, 35 the Kaplan-Meier estimated rate of death or graft loss at month 84 was numerically lower in cyclosporine-treated black vs nonblack patients (13.7% vs 22.5%, respectively); however, this finding may reflect the small number of blacks enrolled in BENEFIT (n = 55).
Kaplan-Meier estimated rates of death or graft loss at month 84 in BENEFIT-EXT were similar in belatacept-treated blacks (27.0%-34.6%) and nonblacks (34.1%-34.8%). These rates were also comparable with those reported in the overall intention to treat populations at 7 years post-transplant (33.4%-34.7%). 31 In keeping with previously reported rates, 35 the Kaplan-Meier estimated rate of death or graft loss at month 84 was numerically greater for cyclosporinetreated black vs nonblack patients (54.9% vs 32.9%, respectively). Despite their shared ancestral origins, it is possible that these 3 patient subsets differed not only in terms of living in disparate geographic regions, but also in terms of underlying immunologic risk. Thus, conclusions drawn from the overall dataset may not be applicable to patients in all regions (or even outside the confines of the clinical trial setting where adherence is likely higher than in clinical practice), but they do suggest that efficacy and safety in belatacept-treated patients are not influenced by race. The similarity in outcomes in the black and nonblack subgroups is supported by population pharmacokinetic analyses, which found race to have minimal clinical impact on belatacept pharmacokinetics. 38 To conclude, we found belatacept-treated black patients to be at similar risk of death or graft loss and AR as belatacept-treated nonblack patients. In both racial subgroups, renal function improved over 7 years for belatacept-based treatment but declined for cyclosporine-based immunosuppression. Estimated mean GFR was generally similar in blacks and nonblacks administered belatacept, and no new belatacept safety signals emerged when stratifying patients by race.
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